Chlorpromazine in the treatment of schizophrenia and manic depression
DOI:
https://doi.org/10.15381/anales.v40i3.10786Abstract
The results of treatment with chlorpromazine (Largactil) -a dose of 100 to 600 mg regimen are presented. daily, alone or combined with sedatives and electroplexia, for the time necessary to obtain a change in symptoms or for a minimum of three months, without attempting a cure of sleep cause in 26 schizophrenic patients, of various types, and 6 manic , of which 5 were in manic depressive phase, 1-anxious to begin the healing phase. All patients had more than 6 months of illness; Schizophrenics and 22 manic all had more than one year of disease. In all cases of schizophrenia treatments were applied pre-emergence but no improvement then treated with chlorpromazine was obtained. The results were: among schizophrenics 7 complete remissions, 4 social referrals, 6 improvements, 8 no improvement and 1 death; among patients with manic psychosis 4 complete remissions and 2 deaths. Influenced symptoms both in terms schizophrenic manic, were side, although the primary symptoms were changed. The results obtained suggest that chlorpromazine should be considered a fundamental treatment in these endogenous psychoses, particularly as the results obtained with it are improvements to those achieved with other treatments in earlier phases of manic-depressive psychosis and in the same outbreak schizophrenia. Presents and discusses the complications and causes of death, with emphasis on the acceptance of the treatment by patients.Downloads
Published
1957-09-16
Issue
Section
Trabajos originales
License
Copyright (c) 1957 Mariano Querol, Fernando Samanez, Manuel Almeida
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Those authors who have publications with this magazine accept the following terms:
- Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
- Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
- Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).
How to Cite
1.
Querol M, Samanez F, Almeida M. Chlorpromazine in the treatment of schizophrenia and manic depression. An Fac med [Internet]. 1957 Sep. 16 [cited 2024 Jul. 17];40(3):729-46. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/10786